Our current study’s findings demonstrate that RLS-0071 can inhibit MPO oxidative activity and dose-dependently reduce NET formation in vivo triggered by a variety of potent inflammatory stimuli that contribute to the pathogenesis of cystic fibrosis. Here, MPO is linked to cystic fibrosis.